Not content with its journey so far in becoming one of the leading contract development and manufacturing organizations (CDMOs) and the achievements of its Samsung Bioepis venture in the biosimilars field, Samsung Biologics appears to have ambitions in another burgeoning space.
According to a report in PULSE by Maeil Business News Korea, Samsung Biologics will explore M&A opportunities to add cell and gene therapy to its portfolio.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze